Relay Therapeutics, Inc. (RLAY) Ownership
RLAY ownership summary
as of October 18, 2026- Institutions
- 110.9% of shares outstanding
- Insiders
- 1.58% of shares outstanding
- Shares outstanding
- 219.1M
- Float
- 145.5M shares available to trade
- Short interest
- 24.84% 46.7M shares short
- Days to cover
- 13.32 short interest up 5.1% vs prior month
- Institutions 110.91%
- Insiders 1.58%
RLAY top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 12.73% | 27.9M | $454.3M | — | June 30, 2026 |
| 2 | FMR Inc | 9.18% | 20.1M | $327.4M | +16.4M (+444.2%) | June 30, 2026 |
| 3 | Casdin Capital, LLC | 7.32% | 16.0M | $261.1M | +1.6M (+11.2%) | June 30, 2026 |
| 4 | BlackRock Inc | 6.98% | 15.3M | $248.9M | +2.3M (+17.8%) | June 30, 2026 |
| 5 | Perceptive Advisors LLC | 6.44% | 14.1M | $229.6M | +4.4M (+44.7%) | June 30, 2026 |
| 6 | COMMODORE CAPITAL LP | 5.48% | 12.0M | $195.4M | −5.0M (−29.4%) | June 30, 2026 |
| 7 | State Street Corp | 4.62% | 10.1M | $164.8M | +3.9M (+62.4%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 4.09% | 9.0M | $145.9M | +1.6M (+21.3%) | June 30, 2026 |
| 9 | T. Rowe Price Associates, Inc. | 3.52% | 7.7M | $125.5M | +5.8M (+300.5%) | June 30, 2026 |
| 10 | Nextech Invest, Ltd. | 3.09% | 6.8M | $110.3M | +1.2M (+22.6%) | June 30, 2026 |
| 11 | Bellevue Group AG | 2.82% | 6.2M | $100.7M | −1.6M (−20.6%) | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 2.16% | 4.7M | $76.9M | +1.2M (+34.6%) | June 30, 2026 |
| 13 | TCG Crossover Management, LLC | 1.95% | 4.3M | $69.6M | — | June 30, 2026 |
| 14 | AllianceBernstein L.P. | 1.87% | 4.1M | $66.7M | +4.0M (+2,719.7%) | June 30, 2026 |
| 15 | Morgan Stanley - Brokerage Accounts | 1.76% | 3.9M | $62.7M | +2.4M (+168.9%) | June 30, 2026 |
| 16 | Siren, L.L.C. | 1.67% | 3.6M | $59.4M | +3.6M (0.0%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 1.56% | 3.4M | $55.5M | +866,840 (+34.1%) | June 30, 2026 |
| 18 | Westfield Capital Management Company, L.P. | 1.53% | 3.3M | $54.4M | +3.3M (0.0%) | June 30, 2026 |
| 19 | Kynam Capital Management, LP | 1.51% | 3.3M | $53.7M | +1.9M (+131.7%) | June 30, 2026 |
| 20 | Dimensional Fund Advisors, Inc. | 1.43% | 3.1M | $50.9M | +187,028 (+6.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 16 holders added 54.7M shares and 2 cut 6.6M.
RLAY top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.11% | 6.8M | $111.0M | −9,256 (−0.1%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.23% | 4.9M | $79.7M | −93,150 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.15% | 4.7M | $76.8M | −54,400 (−1.1%) | September 30, 2026 |
| 4 | Fidelity Select Health Care | 0.95% | 2.1M | $33.9M | — | August 31, 2026 |
| 5 | Strategic Advisers Fidelity US TtlStk | 0.89% | 1.9M | $31.6M | +16,300 (+0.8%) | August 31, 2026 |
| 6 | Fidelity Small Cap Growth | 0.88% | 1.9M | $31.2M | +237,300 (+14.1%) | July 31, 2026 |
| 7 | Fidelity Advisor Biotechnology I | 0.84% | 1.9M | $30.1M | — | August 31, 2026 |
| 8 | Harbor Small Cap Growth Instl | 0.83% | 1.8M | $29.5M | +158,790 (+9.6%) | September 30, 2026 |
| 9 | Fidelity Small Cap Index | 0.81% | 1.8M | $28.8M | +15,462 (+0.9%) | July 31, 2026 |
| 10 | Polar Capital Biotech S Inc | 0.77% | 1.7M | $27.6M | — | August 31, 2026 |
| 11 | Fidelity Stock Selector Small Cap | 0.77% | 1.7M | $27.4M | — | July 31, 2026 |
| 12 | Fidelity Select Biotechnology | 0.75% | 1.6M | $26.7M | — | August 31, 2026 |
| 13 | T. Rowe Price Small-Cap Stock | 0.71% | 1.5M | $25.2M | +37,909 (+2.5%) | September 30, 2026 |
| 14 | T. Rowe Price Integrated US Sm Gr Eq | 0.62% | 1.4M | $22.2M | — | September 30, 2026 |
| 15 | iShares Russell 2000 Growth ETF | 0.61% | 1.3M | $21.8M | −1,697 (−0.1%) | September 30, 2026 |
| 16 | iShares Biotechnology ETF | 0.61% | 1.3M | $21.8M | −10,120 (−0.8%) | September 30, 2026 |
| 17 | T. Rowe Price Health Sciences | 0.58% | 1.3M | $20.8M | — | September 30, 2026 |
| 18 | T. Rowe Price New Horizons | 0.58% | 1.3M | $20.8M | −158,067 (−11.0%) | September 30, 2026 |
| 19 | Pictet-Biotech P USD | 0.52% | 1.1M | $18.4M | −4,593 (−0.4%) | June 30, 2026 |
| 20 | Vanguard Russell 2000 ETF | 0.48% | 1.1M | $17.2M | +129,414 (+13.9%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RLAY insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-09 | Thomas Catinazzo | Sell | $15.00 | 1,800 | $27,000 |
| 2026-04-07 | Thomas Catinazzo | Sell | $13.01 | 17,717 | $230,498 |
| 2026-01-28 | Donald A Bergstrom | Sell | $8.45 | 2,686 | $22,697 |
| 2026-01-28 | Peter Rahmer | Sell | $8.45 | 1,354 | $11,441 |
| 2026-01-28 | Thomas Catinazzo | Sell | $8.45 | 1,695 | $14,323 |
| 2026-01-27 | Donald A Bergstrom | Sell | $7.62 | 18,895 | $143,980 |
| 2026-01-27 | Peter Rahmer | Sell | $7.62 | 11,684 | $89,032 |
| 2026-01-27 | Thomas Catinazzo | Sell | $7.62 | 13,820 | $105,308 |
| 2026-01-06 | Sanjiv Patel | Sell | $7.82 | 43,168 | $337,574 |
| 2025-11-03 | Sanjiv Patel | Sell | $7.00 | 62,073 | $434,511 |
| 2025-10-29 | Peter Rahmer | Sell | $7.50 | 21,394 | $160,455 |
| 2025-10-28 | Thomas Catinazzo | Sell | $7.29 | 21,664 | $157,931 |
| 2025-10-28 | Peter Rahmer | Sell | $7.29 | 19,135 | $139,494 |
| 2025-10-28 | Donald A Bergstrom | Sell | $7.29 | 30,897 | $225,239 |
| 2025-07-29 | Brian Adams | Sell | $3.68 | 18,276 | $67,256 |
| 2025-07-29 | Donald A Bergstrom | Sell | $3.68 | 26,701 | $98,260 |
| 2025-07-29 | Peter Rahmer | Sell | $3.68 | 15,724 | $57,864 |
| 2025-07-29 | Thomas Catinazzo | Sell | $3.68 | 18,380 | $67,638 |
| 2025-07-28 | Brian Adams | Sell | $3.74 | 1,637 | $6,122 |
| 2025-07-28 | Donald A Bergstrom | Sell | $3.74 | 4,069 | $15,218 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RLAY shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RLAY
Institutional investors own 110.9% of Relay Therapeutics's shares and insiders 1.58%. The largest holder is SB INVESTMENT ADVISERS (UK) LTD with 12.73% of the shares (27.9M), as of June 30, 2026. Among the top 20 institutions, 16 added shares and 2 reduced their stake in the latest filings. Short interest is 24.84% of the float, or 13.32 days of average trading volume. The share count rose 4,378.2% since 2019.
Related: RLAY analyst forecast, RLAY key metrics. See the RLAY stock overview for the latest quote and news.
RLAY ownership FAQ
Who owns the most Relay Therapeutics stock?
The largest shareholders of Relay Therapeutics are SB INVESTMENT ADVISERS (UK) LTD (12.73%), FMR Inc (9.18%), Casdin Capital, LLC (7.32%), BlackRock Inc (6.98%), Perceptive Advisors LLC (6.44%).
What percentage of Relay Therapeutics is owned by institutions?
Institutions hold 110.9% of Relay Therapeutics's shares outstanding; insiders hold 1.58%.
Which funds own Relay Therapeutics?
The largest fund holders of Relay Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (3.11%), State Street® SPDR® S&P® Biotech ETF (2.23%), iShares Russell 2000 ETF (2.15%), Fidelity Select Health Care (0.95%), Strategic Advisers Fidelity US TtlStk (0.89%).
What is Relay Therapeutics's short interest?
46.7M shares of Relay Therapeutics were sold short, 24.84% of the float; at the average daily volume it would take 13.32 days to cover.
Are insiders buying or selling Relay Therapeutics?
Of the latest 20 reported insider transactions in Relay Therapeutics (since July 28, 2025), 0 were purchases and 20 were sales.
How many shares of Relay Therapeutics are outstanding?
Relay Therapeutics has 219.1M shares outstanding, of which 145.5M are in the public float.